Meckel-Gruber syndrome (MKS) is a perinatally lethal disorder characterized by the triad of occipital encephalocele, polydactyly and polycystic kidneys. Typical of other disorders related to defective primary cilium (ciliopathies), MKS is genetically heterogeneous with mutations in a dozen genes to date known to cause the disease. In an ongoing effort to characterize MKS clinically and genetically, we implemented a gene panel and next-generation sequencing approach to identify the causal mutation in 25 MKS families. Of the three families that did not harbor an identifiable causal mutation by this approach, two mapped to a novel disease locus in which whole-exome sequencing revealed the likely causal mutation as a homozygous splicing variant in TMEM107, which we confirm leads to aberrant splicing and nonsense-mediated decay. TMEM107 had been independently identified in two mouse models as a cilia-related protein and mutant mice display typical ciliopathy phenotypes. Our analysis of patient fibroblasts shows marked ciliogenesis defect with an accompanying perturbation of sonic hedgehog signaling, highly concordant with the cellular phenotype in Tmem107 mutants. This study shows that known MKS loci account for the overwhelming majority of MKS cases but additional loci exist including MKS13 caused by TMEM107 mutation.
Introduction
Meckel-Gruber syndrome (MKS) is a ciliopathy caused by defective primary cilium, a non-motile microtubule-based organelle that plays an increasingly recognized role in cellular homeostasis and organismal development (1) . Some ciliopathies are considered 'classical', such as MKS, Bardet-Biedl syndrome, Joubert syndrome, oral-facial-digital syndrome, acrocallosal syndrome and nephronophthisis, and are thought to represent a spectrum of phenotypic severity involving a subset of organs (neural tube, digits, eyes, kidneys and limbs), whereas primary microcephaly and primordial dwarfism, while clearly displaying cilia-related defects, lack the core clinical features of classical ciliopathies for unclear reasons (2) . Within the group of classical ciliopathies, MKS represents the extreme end of the spectrum with pronounced involvement of all core organs resulting in occipital encephalocele, polydactyly, microphthalmia, polycystic kidneys, ductal plate malformation/liver fibrosis and almost always perinatal death (3) .
MKS, like other ciliopathies, is genetically heterogeneous with a dozen genes known to be mutated in this disease (MKS1-12), all in an autosomal recessive fashion. In agreement with a model that views classical ciliopathies as a continuum in a phenotypic spectrum, several MKS genes have been found to be mutated in other less severe ciliopathies. For example, mutations in MKS1 can cause Bardet-Biedl syndrome; TMEM216, CEP290, RPGRIP1L, CC2D2A, TMEM231 and NPHP3 can cause nephronophthisis and all MKS genes have been associated with Joubert syndrome except NPHP3, B9D2 and KIF14 (4, 5) . The mechanism for this phenotypic variability is not clear, but it is likely to be primarily driven by the nature of the causal alleles themselves (6) . We have shown previously that the overwhelming majority of MKS cases can be explained by mutations not only in known MKS disease genes but also in other disease genes that can lead to overlapping or even identical phenotype, e.g. EVC2 (7) . Nonetheless, that study also showed that additional MKS loci likely exist, albeit accounting for a diminishing fraction of cases, as shown by the subsequent discovery of TMEM231 and KIF14 (4, 8) .
Massively parallel sequencing (aka next-generation sequencing) has revolutionized genomics and its medical applications (9) . Combining all known disease genes in a single panel that is sequenced simultaneously offers a high-throughput alternative to the prioritization of candidate genes for Sanger sequencing (10) . MKS represents an ideal candidate for this approach owing to its marked genetic heterogeneity and the fact that known disease genes account for the majority of cases. In view of the relatively common occurrence of MKS in Saudi Arabia due to the high rate of consanguinity (11), we proposed to use this approach to identify the likely causal mutation and at the same time define cases that lack mutations in known disease genes, thus presenting an opportunity for novel disease gene discovery. Here, we describe the successful implementation of this strategy to identify the causal mutation in the majority of the study cohort and to highlight two families with a likely novel cause, which we subsequently show using whole-exome sequencing to be a mutation in TMEM107.
Results

Human subjects
A total of 26 cases, representing 25 families with at least one case that met our clinical definition of MKS, were enrolled (only one previously published: 12DG0850). All families were consanguineous, and 72% were multiplex (Supplementary Material, Fig. S1 ). Supplementary Material, Table S2 summarizes the clinical features of all study families, and Figure 1) shows representative clinical images. Expanding the allelic heterogeneity of MKS Consistent with our earlier study (7) , the majority of families (19/ 25) were found to have a likely causal mutation in one of the known MKS genes. A total of 12 different mutations (including 6 novel) in 6 MKS genes were identified (Table 1 and Supplementary Material, Fig. S2 ). We note the identification of a second novel mutation in TCTN2, which has been linked previously to MKS based on a single founder mutation, therefore clearly confirming TCTN2 as MKS8 (13) . In one consanguineous family (13DG0030), the two affected children were found to harbor compound heterozygous mutations in TMEM67, which would have been missed using traditional homozygosity mapping approach, thus showing the power of the gene panel method. Consistent with the known allelism of MKS with other ciliopathies, we also identified (14). This is interesting because although it is known that mutations in Walker-Warburg disease genes can narrowly phenocopy MKS (occipital encephalocele and perinatal lethality), we reckoned that multicystic kidneys would be a distinctive feature of MKS. However, this case as well as two previously published cases with B3GNT1 mutation clearly shows the challenge in differentiating these overlapping diagnoses, hence the importance of molecular studies (14, 15) .
Identification of MKS13 defined by TMEM107 mutation
Of the remaining three unsolved families in our cohort, two (12DG1045 and 14DG0220) were found to share a single founder haplotype, despite being apparently unrelated, thus suggesting an unrecognized distant ancestor carrier of a causal MKS mutation ( Fig. 2B ). This MKS13 locus (chr17:6 860 607-11 316 401) is novel and spans 30 genes. Whole-exome sequencing of the index in one of the two families revealed a total of 97 homozygous coding/splicing homozygous variants within the critical locus. However, only one of these variants was novel: TMEM107 (NM_032354: c.274+1G>A). This variant is absent in 573 Saudi exome files and the ExAC database and has a combined annotation dependent depletion score of 26.3. Reverse transcriptase-polymerase chain reaction (RT-PCR) using fibroblast-derived RNA from case 14DG0220 showed, in addition to overall reduction most likely due to nonsense-mediated decay, replacement of the normal transcript by one that has one intronic base pair insertion. This predicts frameshift and premature truncation of the protein (NM_032354.3: p. Ser92Cysfs*7) (Fig. 2C) . Reassuringly, genes within the critical locus received 100% coverage and there were no other novel or even rare variants of frequency <0.01. Furthermore, this homozygous mutation fully segregated with the disease within the two families. The two patients also shared two homozygous regions but with different haplotype on chr2 and chr9 (Supplementary Material, Fig. S4 ). No biallelic variants passed the filtering steps in these two intervals (Supplementary Material, Table S3 ).
TMEM107 is required for normal ciliogenesis in humans
Tmem107 mutant mice develop exencephaly (akin to encephalocele), embryonic lethality and polydactyly, features that recapitulate MKS in humans (16, 17) . In these mice, ciliogenesis is markedly reduced and the few ciliated mouse embryonic fibroblasts develop abnormally long and curly cilia. Remarkably, each of these abnormalities was faithfully recapitulated in fibroblasts derived from the patient with the TMEM107 loss-of-function mutation. As shown in Figure 3 , the number of ciliated cells is significantly reduced compared with controls (26 versus 83 and 89%, P < 3.6E−18, two-tailed t-test). The few ciliated cells have excessively elongated cilia with an average length of 4.8 µm compared with an average of 2.9 and 3.2 µm in controls (two biological controls were used for comparison) (P < 0.001, two-tailed t-test) and a curly pattern was also noticed (Supplementary Material, Fig. S3 ).
Taken together, we conclude that the loss-of-function mutation in TMEM107 impairs ciliogenesis in human cells in a pattern nearly identical to that observed in the corresponding mouse models.
TMEM107 loss-of-function mutation perturbs sonic hedgehog signaling
The primary cilium is critical for proper sonic hedgehog (SHH) signaling, and impaired SHH signaling is frequently reported in studies involving MKS patient cells (18) (19) (20) (21) . Furthermore, Tmem107 mutants were found to have major disruption of SHH signaling (16) . In concordance with these observations, we tested patient fibroblasts with the TMEM107 loss-of-function mutation and found marked suppression of smoothened agonist (SAG)-induced SHH signaling, using GLI1 expression as a readout, when compared with two control fibroblast cell lines (Fig. 3 ) and markedly reduced translocation of SMO to the cilium in patient versus control cells (Supplementary Material, Fig. S5) . Therefore, the requirement for TMEM107 for normal SHH signaling in mouse appears to be conserved in humans and that the mutation we report significantly impairs that function. It is worth noting that failure of induction of SHH signaling by SAG was also previously found in fibroblast cells from patients with mutation in other MKS genes (5).
Discussion
Significant progress has been made in deciphering the genetic heterogeneity of MKS, and we have reached a stage where mutations in known disease genes account for the majority of cases (7). Nonetheless, additional disease loci likely exist although their contribution to the mutation pool will be diminishingly (26 versus 83 and 89%, P < 3.6E−18, two-tailed t-test) and the average cilia length in affected fibroblast compared with two controls (P < 0.001, two-tailed t-test).
Cilia size was measured using Image J software. (D) GLI1 expression is markedly suppressed in fibroblasts from case 14DG0220 than in two control fibroblasts in response to SAG stimulation. Result is the average for three independent experiments.
smaller. These novel loci could be known disease genes for other ciliopathies given the known allelism between MKS and these diseases as discussed above. Indeed, our study shows that TCTN1, hitherto reported to be mutated only in Joubert syndrome (22) , can be mutated in patients who fully meet the classical definition of MKS. The clinical overlap between B3GNT1-related Walker-Warburg syndrome and MKS is remarkable and poses a difficult differential diagnosis to exclude prenatally. We also note that in this and in previous cohorts, polydactyly was not always present so just as the presence of polycystic kidneys is not pathognomonic, lack of polydactyly does not exclude the diagnosis either (4,7,13). The remarkably diverse proteome of the primary cilium suggests that completely novel ciliopathy genes are likely to be discovered. Large-scale mutagenesis screens in model organisms and forward genetics approaches have supported the candidacy of an increasing number of genes for playing a role in human ciliopathies (23) . Consanguineous families, on the other hand, in which randomly occurring inactivating alleles are rendered homozygous as a function of autozygosity, have been a major source of establishing a definitive disease link for these candidate ciliopathy genes. In the case of TMEM107, we are fortunate that the two lines of evidence converge to strongly support its designation as a novel disease gene for MKS.
TMEM107 belongs to a very large family of transmembrane proteins. Through a forward genetics approach to map the causal mutation of N-ethyl-N-nitrosourea-induced schlei mutants, a missense mutation in Tmem107 was identified (17) . Because these mutants display typical ciliopathy-equivalent features including exencephaly, polydactyly and early lethality, it was proposed that the underlying gene encodes a ciliary protein (16) . Indeed, detailed analysis of these mice was consistent with Tmem107 being a gene essential for normal ciliary biology. At an organismal level, these mice have a markedly abnormal SHH signaling in the digits and neural tube. Specifically, the Tmem107 mutants have lack of ventral cell specification at the floor of the neural tube, leading to a neural tube closure defect in the form of exencephaly, which may be equivalent to the occipital encephalocele observed in our patients (16) . Conversely, the SHH expression domain is markedly expanded in the developing limbs leading to an increased number of digits, which corresponds to the MKS-related polydactyly (16) . Our own analysis of patient fibroblasts also seems consistent with an important role played by TMEM107 in SHH signaling given the marked suppression of SAG-induced SHH signaling in these cells. Reassuringly, an independent Tmem107 allele was also characterized and the embryonic phenotype was highly concordant (16) .
At a cellular level, Tmem107 mutants have a marked ciliogenesis defect as evident by the study of mouse embryonic fibroblasts in which the number of ciliated cells was significantly diminished. Surprisingly, the few ciliated fibroblasts had abnormally long and dysmorphic cilia. All these features were faithfully recapitulated in the fibroblasts from a patient with TMEM107 loss-of-function mutation consistent with a highly conserved ciliary function played by the encoded protein across species (16) . Of note, mice with a missense mutation in Tmem107 did not have cystic kidney disease unlike our patients. This could be due to interspecies differences but could also reflect the apparently more severe nature of the human mutation compared with that of the schlei mutants.
In conclusion, we show that loss of function in TMEM107 is associated with a classical MKS phenotype and abnormal ciliogenesis. Our data are consistent with two independent mouse mutants of its ortholog, lending further credence to our proposal to assign TMEM107 as MKS13. Future studies will hopefully shed light on the mechanism by which TMEM107 contributes to normal ciliary biology and the magnitude of its contribution to the overall mutation pool of MKS.
Materials and Methods
Human subjects
MKS cases were defined on the basis of occipital encephalocele, perinatal lethality and either polydactyly or polycystic kidneys. Parents of deceased children who met the clinical definition were eligible for recruitment even if the index was not available for sampling. Recruitment followed obtaining a written informed consent under an Institutional Review Board-approved protocol (KFSHRC RAC# 2080006). Blood was collected in ethylenediaminetetraacetic acid and, when possible, in sodium heparin tubes for DNA and establishment of lymphoblastoid cell lines, respectively. A skin biopsy was always attempted but was only successful in a very small number of cases.
Gene panel
Details of the gene panel will be described elsewhere (24) . Briefly, a next-generation multiplexing assay was developed where the 'OMIM' database was manually curated for genes with confirmed causal links to diseases. The resulting list of ∼3000 genes were included in 13 clinically themed panels. Genes were amplified using the AmpliSeq HiFi mix and proprietary primer design (Thermo Fisher, Carlsbad, CA, USA) followed by sequencing on the Ion Proton platform following the manufacturer's protocol. For the purpose of this article, we will only describe the results as they pertain to the MKS cohort. The specific ciliopathy-associated genes included in the Mendeliome are listed in Supplementary Material, Table S1 .
Autozygosity mapping
MKS cases in which no likely causal mutation was identified by the gene panel were analyzed using autozygosity mapping as described before (25) . Briefly, genomewide genotyping using Axiom SNP chip array was followed by mapping of runs of homozygosity (ROH) >2 Mb in size as surrogates of autozygosity using AutoSNPa (26) , which also delineates the haplotype structure, thus allowing the detection of haplotype sharing across families.
Whole-exome sequencing and variant calling algorithm
One hundred nanograms of each DNA sample was treated to obtain the Ion Proton AmpliSeq library. Briefly, DNA was amplified in 12 separate wells using Exome Primer Pools, AmpliSeq HiFi mix (Thermo Fisher) and 10 amplification cycles. All 12 PCR pools were combined in one well and subjected to primer digestion performing incubation with FuPa reagent (Thermo Fisher). Amplified exome targets were ligated with Ion P1 and Ion Xpress Barcode adapters. After purification, libraries were quantified using quantitative PCR (qPCR) with the Ion Library Quantification Kit (Thermo Fisher). The prepared exome library was further used for emulsion PCR on an Ion OneTouch System and templated Ion Sphere particles were enriched using Ion OneTouch ES, both procedures following the manufacturer's instructions (Thermo Fisher). The template-positive Ion PI Ion Sphere particles were processed for sequencing on the Ion Proton instrument (Thermo Fisher). Approximately 15-17 Gb of sequence was generated per sequencing run. Reads were mapped to UCSC hg19 (http:// genome.ucsc.edu/) and variants identified using the Saudi Human Genome Program pipeline.
The output of the sequencing machine is a set of read files in BAM format. The reads were first examined to trim low-quality parts from the reads; bases with quality <20 were trimmed out. The reads were then aligned to the reference using the human genome (hg19) using the program TMAP. After the alignment, the reads were processed to call the variants using the program TVC (Torrent Variant Caller). The programs tmap and TCV were recommended by the manufacturer as they take basic signal information into account. Both were distributed as part of the Torrent Suite (https://github.com/iontorrent/TS) package. The output of the variant calling step was a list of variants in VCF file format. The variant VCF files were then annotated through an annotation pipeline including public and commercial knowledge databases in addition to in-house database of Saudi mutations. The public databases include the ones that are distributed within the Annovar package (27) , including RefSeq, OMIM, Genbank, dbSNP and 1000 genome. In addition, the variants were annotated with pathogenicity scores, homozygosity/heterozygosity and other parameters used to identify candidate causative variants. The damaging effect of a variant was predicted using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph/), SIFT (http:// blocks.fhcrc.org/sift/SIFT.html) and Mutation Taster (http:// www.mutationtaster.org/). The prioritization and filtration of the variants was based on different criteria including low-quality score, variant location (coding regions or not), functional change (e.g. non-synonymous, non-frameshift) and frequency in different population databases.
Relative qRT-PCR
Total RNA from patient and two control fibroblast cell lines were extracted using the QIAamp RNA Mini Kit (Qiagen Inc., Germantown, MD) and DNase treated by the RNase-Free DNase Set (Qiagen), according to the manufacturer's recommendations. Preparation of the cDNA was carried out using the iScript™ cDNA synthesis kit and poly-T oligonucleotide primers (Applied Biosystems, Carlsbad, CA). Two set of primers for TMEM107 cDNA were designed to specifically amplify the cDNA (TMEM107 exon 1-5: 5′-TTGTGCCCTCTCGCTTCC-3′ and 3′-GGTGACGAATAAAGC CATT-5′ and TMEM107 exon 2-4: 5′-CTGCCTGCCTCTCACGTT-3′ and 3′-TAGTGCACTCCCAACGCTC-5′). Relative quantification (q) RT-PCR for the expression TMEM107 in affected individual fibroblast and two fibroblast controls was performed using SYBR green and Applied Biosystems 7500 Fast Real-Time PCR System.
Ciliogenesis assay
For analysis of ciliogenesis, patient (14DG0220) and two control skin fibroblast cells were plated onto coverslip, cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, glutamine and penicillin and streptomycin for 24 h. Medium was replaced with Opti-MEM (GIBCO) without serum and cultured for 72 h. Cells were fixed in 3.6% paraformaldehyde for 10 min, then permeabilized with 0.1% Triton X-100 (Sigma) followed by blocking in goat serum and then stained with antibodies [anti-acetylated α-tubulin (SigmaT7451) and IFT88 (Proteintech 13967-1-AP)]. The unbound antibody was washed with phosphate buffered saline and incubated with fluorescent-dye-conjugated secondary antibodies (ImmunoPure, Thermo Scientific), the coverslips were mounted in VectaShield containing 4',6-diamidino-2-phenylindole (DAPI) (Vector Labs) and cells were observed under a fluorescent microscope (Nikon Eclipse 90i). For cilia forming frequency, >300 cells were counted for tubulin-stained cilia. Image J was used for measuring the length of 20 tubulin-stained cilia from each cell line.
SHH signaling assay
Patient (14DG0220) and two control fibroblast cells were seeded to 70% confluence in minimal essential medium in two sets. The medium was replaced with Opti-MEM-reduced serum medium and one set was treated with SAG (Smoothened Agonist Sc-202814; Santa Cruz Biotechnology) at concentration of 100 n, whereas the other set was treated with dimethyl sulfoxide (DMSO). The cells were collected after 18-21 h for RNA extraction and realtime PCR using GLI1 primers (5′-AGAGAGACCAACAGCTGCAC-3′; 3′-TCATCTGGGCTGGGAATC-5′). The experiment was performed in triplicate.
For the immunostaining experiment, patient (14DG0220) and two control skin fibroblast cells were plated onto coverslip, cultured in DMEM supplemented with 10% fetal bovine serum, glutamine and penicillin and streptomycin for 24 h. The medium was replaced with Opti-MEM-reduced serum medium and one set was treated with SAG (Smoothened Agonist Sc-202814; Santa Cruz Biotechnology) at a concentration of 100nM, whereas the other set was treated with DMSO for 72 h. The cells were fixed, permeabilized and blocked as described above and then stained with antibodies Smo [Smo Antibody (E-5): sc-166685, Santa Cruz Biotechnology] (green) and the ciliary marker acetylated α-tubulin (Cell Signaling Technology, #3971) (red). The cells are incubated with fluorescent-dye-conjugated secondary antibodies (ImmunoPure, Thermo Scientific), the coverslips were mounted in VectaShield containing DAPI (Vector Labs) and the cells were observed under a fluorescent microscope (Nikon Eclipse 90i).
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Supplementary Material is available at HMG online.
